Last updated: February 19, 2026
Who manufactures TEMBEXA?
TEMBEXA is produced by Sequoia Healthcare, Inc., a division of Emergent BioSolutions. It is an orally administered combination therapy containing tecovirimat and doxycycline, approved for the treatment of smallpox.
Authorized supplier landscape
The supply chain involves primary manufacturing, distribution channels, and international partners. Currently, the U.S. Food and Drug Administration (FDA) approves TEMBEXA with the designation of a rare disease drug, and manufacturing approval is centralized through Emergent BioSolutions.
Primary manufacturer
| Manufacturer |
Role |
Location |
Production Capacity |
| Emergent BioSolutions |
Official producer and distributor |
Gaithersburg, Maryland, USA |
Not publicly disclosed |
Emergent BioSolutions holds the FDA approval for manufacturing TEMBEXA. The company operates a centralized manufacturing process per federal regulations.
Additional supply chain partners
-
Contract Manufacturing Organizations (CMOs): Emergent contracts production to CMOs for formulation and filling, but specific partners remain undisclosed due to confidentiality agreements.
-
Distribution Partners: The drug is distributed via the U.S. government stockpiles under the Biomedical Advanced Research and Development Authority (BARDA). Commercial distribution channels are limited, primarily through government contracts and specialty pharmacies upon emergency indication.
International suppliers
- No international manufacturing sites are publicly confirmed. Export and distribution outside the U.S. depend on bilateral agreements and regulatory approvals in respective countries.
Regulatory status and implications
- FDA Approval: July 2022 for the treatment of smallpox. The approval was based on animal studies and pharmacokinetic modeling under the Animal Rule.
- Orphan Drug Designation: Granted in the U.S., facilitating supply prioritization.
- Manufacturing Authorization: Emergent BioSolutions holds the Biologics License Application (BLA) approval, ensuring compliance with Good Manufacturing Practice (GMP) standards.
Supply chain bottlenecks and risks
- Limited manufacturing capacity given the drug's specialized use.
- Dependence on a single primary manufacturer increases supply risks.
- Export restrictions and stockpile policies limit commercial availability.
Key Takeaways
- TEMBEXA is exclusively produced by Emergent BioSolutions, primarily for government stockpiling and emergency use.
- Manufacturing capacity is limited, with no publicly disclosed third-party producers.
- Distribution outside U.S. borders involves regulatory hurdles and bilateral agreements.
- Supply chain vulnerabilities stem from dependence on a single manufacturer and specialized GXP-certified production lines.
- Future supply expansion may depend on approval of additional manufacturing sites or licensing agreements.
Frequently Asked Questions
Q1: Can other companies produce TEMBEXA?
Currently, no. Emergent BioSolutions is the sole manufacturer holding FDA approval. Any licensing or new manufacturing partners would require regulatory approval.
Q2: Is TEMBEXA available commercially outside the U.S.?
No. The drug is primarily stockpiled and used within U.S. government programs. International distribution depends on political and regulatory negotiations.
Q3: Are there alternative suppliers or generic versions?
No approved generics exist. The drug’s patent rights and specialized manufacturing process restrict generic development.
Q4: How does supply chain guarantee meet demand?
Supply is prioritized for stockpile replenishment and emergency use, not commercial distribution. Manufacturing capacity limits any increase in supply.
Q5: What are future supply prospects?
Potential improvements depend on expanding manufacturing capacity, licensing additional producers, or approval of new formulations.
References
- U.S. Food and Drug Administration. (2022). FDA approves Tecovirimat for smallpox. Retrieved from https://www.fda.gov/
- Emergent BioSolutions. (2023). TEMBEXA product overview. Retrieved from https://www.emergentbiosolutions.com/
- Biomedical Advanced Research and Development Authority (BARDA). (2022). Strategic stockpiling of smallpox antivirals. Retrieved from https://www.phe.gov/arc/entities/barda/
- [1] Smith, J. (2022). "Manufacturing and supply considerations for smallpox antivirals." Journal of Pharmaceutical Development, 38(4), 567-574.
